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Summary Two patients with proven 5-fluorouracil (5-FU)-associated cardiotoxicity were treated with the specific thymidylate synthase
inhibitor raltitrexed safely, without evidence of cardiotoxicity. Raltitrexed might be an alternative for patients with advanced colorectal cancer
and 5-FU-associated cardiotoxicity. 5-FU cardiotoxicity is not due to the antineoplastic mechanisms via thymidilate synthase.
Keywords: 5-fluorouracil; cardiotoxicity; raltitrexed; colorectal neoplasms
5-Fluorouracil (5-FU)-associated cardiotoxicity was recognized
18 years after its first clinical use, after symptoms of chest pain
typical ofangina pectoris, in patients treated with 5-FU (Dent and
McColl, 1965). Estimates of its incidence have been given with a
range of 1.6% in larger series (Labianca et al, 1982) and up to 10%
in smaller cohorts (Collins and Weiden, 1987). 5-FU should be
discontinued in the case of cardiotoxicity to avoid the develop-
ment of serious or fatal cardiac damage (Anand, 1994). However,
the arsenal ofeffective antineoplastic compounds for the treatment
ofcolorectal cancer is limited, and the identification ofa drug that
may be safely given to patients with cardiac toxicity after 5-FU
administration is important. Here, we report the successful
administration of raltitrexed (Zeneca, Macclesfield, Cheshire,
UK), a new specific thymidylate synthase inhibitor, in two patients
with 5-FU-induced cardiotoxicity.
PATIENTS AND METHODS
Case 1
A 58-year-old female without any history of cardiovascular
disease presented at our institution with lung and liver metastases
of a sigmoid adenocarcinoma. She had received three cycles of
weekly folinic acid 500 mg m-2 as a 2-h infusion and 5-FU 500 mg
m-2 as an i.v. bolus in the middle of the folinic acid infusion
repeated for 6 weeks followed by a 2-week rest period. This
therapy was tolerated well without any cardiac toxicity. When the
tumour progressed, treatment with high-dose 5-FU 2600 mg m-2
given as a weekly 24-h infusion plus folinic acid 500 mg m-2 as a
2-h infusion before 5-FU was initiated. Approximately 22 h after
the start of the 5-FU infusion the patient complained of dyspnoea
Received 30 May 1997
Revised 22August 1997
Accepted 29 September 1997
Correspondence to: C-H Kohne, Robert-Rossle-Klinik, Department
Haematology/Oncology and Tumor Immunology, Virchow-Klinikum,
Medizinische Fakultat der Charite der Humboldt-Universitat zu Berlin,
Lindenberger Weg 80, 13125 Berlin, Germany
and retrosternal pain and the 5-FU infusion was stopped. The
blood pressure was 80/60 mmHg and the heart rate was regular
with 100 beats per min. The ECG obtained after onset of symp-
toms revealed non-specific ST segment elevation in the anterior
and posterior leads with a normalization after 24 h (Figures 1 and
2). Serial measurements of serum cardiac enzymes were normal.
One week later, the patient was given the same 5-FU/folinic acid
regimen and also received isosorbide dinitrate, molsidomine and
acetylsalicylic acid. Approximately 10 h afterthe start ofthe 5-FU
infusion, the patient complained of dyspnoea and retrosternal
chest pain. The ECG revealed temporary changes similar to those
observed a week earlier. Again, serial determination of serum
cardiac enzyme levels remained unchanged. An echocardiogram
was normal except for a localized apical hypokinesia. The global
ejection fraction was normal. A myocardial perfusion image
obtained by 210-thallium single photon emission computerized
tomography (SPECT), performed at rest and during exercise,
demonstrated slightly decreased anteroseptal perfusion with late
redistribution. Left ventricular and coronary angiography demon-
strated normal coronary arteries but a slightly globalized decrease
ofleft ventricular pump function. The clinical pattern ofdyspnoea
and angina after repeated 5-FU infusion was therefore best
explained as 5-FU cardiotoxicity. The patient then received
raltitrexed 3 mg m-2 as a short i.v. infusionrepeated every 3 weeks.
She was closely monitored, but no signs of cardiac toxicity
recurred and no further ECG changes were noted (Figures 1 and 2,
E and F in both). The patient received raltitrexed for 3 months
until tumourprogression.
Case 2
A 62-year-old man presented with unresectable liver metastases of
a sigmoid adenocarcinoma. He had a history of coronary artery
disease with two inferiormyocardial infarctions 14 and 22 years ago
and had received coronary bypass grafts to the left anterior
descending artery (LAD) and the left circumflex artery (CX) 12
years prior. Since that time he had been taking a long-acting nitrate
and acetylsalicylic acid and was free of symptoms even when
exposed to moderate physical work. The ECG showed signs ofthe
973974 C-H Kohne etal
A B C D E F
Figure 1 ECG of patient 1 extremity leads. (A and B) First episode of cardiac toxicity. A, before 5-FU; B, after onset of chest pain. (C and D) Second
episode of cardiac toxicity. C, before 5-FU; D, after onset of symptoms. (E and F) Raltitrexed administration. E, before raltitrexed; F, after raltitrexed
administration (3 mg m-2)
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Figure 2 ECG of patient 1, leads Vi to V6. (A and B) First episode of cardiac toxicity. A, before 5-FU; B, after onset of chest pain. (C and D) Second
episode of cardiac toxicity. C, before 5-FU; D, after onset of symptoms. (E and F) Raltitrexed administration. E, before raltitrexed; F, after raltitrexed
administration (3 mg m-2)
myocardial scar but was otherwise normal (Figures 3 and 4). A
weekly treatment with folinic acid 500 mg m-2 given as a 2 hour
infusion followed by 5-FU 2600 mg m-2 as a 24-h infusion was
initiated. Approximately 12 h after the start ofthe 5-FU infusion, he
complained of retrostemal chest pain, which only temporarily
responded to nitroglycerin. Because the symptoms persisted, the
5-FU infusion was stopped. The ECG then recorded during pain
(Figures 3 and 4) revealed non-specific ST segment elevation in the
anterior leads and T-wave inversion in lead Ill. Serial serum cardiac
enzyme measurements remained unchanged. Immediate coronary
angiography demonstrated a severe stenosis ofthe LADbypass graft
and a moderate stenosis of the CX bypass graft. Successful
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Figure 3 ECG of patient 2, extremity leads. (A and B) First episode of 5-FU cardiotoxicity. A, before 5-FU administration; B, after onset of chest pain.
(C-E) Second episode of 5-FU cardiotoxicity. C, before 5-FU administration; D, after onset of chest pain; E, 5 days after cardiotoxicity
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Figure 4 ECG of patient 2, leads Vito V6. (A and B) First episode of 5-FU cardiotoxicity. A, before 5-FU administration; B, after onset of chest pain.
(C-E) Second episode of 5-FU cardiotoxicity. C, before to 5-FU administration. D, after onset of chest pain; E, 5 days after cardiotoxicity
percutaneous transluminal coronary angioplasty (PTCA) with a
stent implantation into the LAD bypass was performed the next day.
Four weeks later, an unremarkable stress ECG confirmed the
patient's well-being. An echocardiogram showed a normal global
ejection fraction. The patient then received four cycles ofraltitrexed
3 mg m-2 as a short i.v. infusion every 3 weeks. This treatment was
well tolerated without any incidence of cardiac toxicity. When the
tumour progressed after the fourth cycle of raltitrexed, he received
bolus 5-FU 425 mg m-2 plus FA 20 mg m-2 given on 5 consecutive
days every 4 weeks. Eight hours after the second administration on
day 2, the patient complained of retrostemal chest pain that again
only temporarily responded to nitroglycerine. The ECG recorded
shortly afterthepainepisodedemonstratedT-wave depression in the
anterior leads, which resolved three days after the event (Figures 3
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and 4). Coronary angiography revealed no restenosis ofthe formerly
treated LAD bypass graft. The symptoms of retrostemal chest pain
were therefore most likely due to 5-FU cardiotoxicity. The patient
remained stable and without episodes of.angina pectoris thereafter.
DISCUSSION
We present two cases of repeated 5-FU induced cardiotoxicity
with no cardiac side-effects after repeated exposure to raltitrexed.
Our first patient had normal coronary arteries as demonstrated
by coronary catheterization. She experienced retrostemal chest
pain accompanied by ECG changes on repeated administration of
high dose infusional 5-FU but had previously tolerated a weekly
bolus regimen. This is a notable observation, which to our knowl-
edge has not been described before and supports the proposed
dose- and/or schedule-dependency of 5-FU induced cardiotoxicity
(Collins and Weiden, 1987; Gamelin et al, 1991; Weidmann et al,
1994). Therefore, it remains possible that our patient might have
tolerated bolus 5-FU without cardiotoxicity. After experiencing
5-FU cardiotoxicity, she could safely receive raltitrexed without
cardiac symptoms or ECG changes on repeated recordings during
raltitrexed treatment.
Our second patient was asymptomatic without angina pectoris
for several years after a coronary artery bypass operation and
required minimal anti-anginal medication. During the infusion of
high dose 5-FU he experienced retrosternal chest pain accompa-
nied by ECG changes in the anterior and posterior leads.
Therefore, the detection of a significant stenosis in the LAD
bypass supplying the anterior wall does not contradict the
postulated role of 5-FU as a causative agent. Additionally, the
retrostemal chest pain accompanied by ECG changes occurred
again when this stenosis was open. The time correlation between
5-FU exposure and cardiac symptoms at rest, and the reversibility
of ECG changes strongly argue in favour of 5-FU as the causative
agent of this patient's cardiac symptoms, even if it might be a
combination of both. It is therefore reasonable to assume that this
patient had 5-FU-induced cardiotoxicity as well as ischaemic heart
disease. Patients with a history ofcoronary heart disease are more
likely to experience 5-FU cardiotoxicity (Labianca et al, 1982). It
may be for this reason that our patient had toxicity when receiving
bolus (low dose) and infusional (high dose) 5-FU. This patient also
received several cycles of raltitrexed without any further episodes
ofchest pain or ECG changes.
Several causative mechanisms for 5-FU cardiotoxicity have
been postulated, including an autoimmune response to damaged
cells (Stevenson et al, 1977), increased oxygen demand in patients
receiving 5-FU (Rezkalla et al, 1989), coronary spasm (Burger and
Mannino, 1987) due to protein kinase C-mediated vasoconstriction
(Mosseri et al, 1993) and the 5-FU contaminant fluoroacetate
(FAC) (Lemaire et al, 1992).
It has been suggested that the cardiotoxic effect of 5-FU itself
may be responsible for 5-FU cardiotoxicity (Villani et al, 1979).
Inhibition ofDNA synthesis by 5- FU incorporated into myocardial
cells was suggested to be the first step of cardiotoxicity (Liss and
Chadwick, 1974), and myocardial depression has been explained
by inhibition ofmitochondrial DNA synthesis due to 5-FU (Akhtar
et al, 1993). Like 5-FU, raltitrexed exerts similar effects on DNA
synthesis. This DNA-directed antimetabolite mechanism is there-
fore a very unlikely cause of5-FU cardiotoxicity. As the recurrence
rate of cardiotoxicity after exposure to 5-FU is thought to be 90%
(Robben et al, 1993), cardiotoxic side-effects after a total of seven
exposures to raltitrexed would have been expected, assuming that
the direct cytotoxic effect on DNA synthesis is responsible for
cardiotoxicity.
Usually, 5-FU based treatment has to be discontinued if the
patient experiences cardiotoxicity (Anand, 1994). The choice of
effective alternative drugs is limited in patients with colorectal
cancer. In metastatic disease, 5-FU-based therapy improves the
quality of life, delays the occurrence of tumour-related symptoms
(Anonymous, 1992) and may prolong survival compared with
patients not receiving chemotherapy (Scheithauer et al, 1993).
Therefore it is important to offer those patients an effective alter-
native treatment. Based on our experience, raltitrexed may be a
candidate. The precise role of this drug relative to 5-FU plus
folinic acid is currently under investigation. Three randomized
trials (Cunningham et al, 1995; Harper, 1997; Pazdur and Vincent,
1997) demonstrated equivalence in the response rates, two ofthese
studies showed a slightly inferior time to progression (4 weeks)
and one trial a shorter median survival (9.7 vs 12.7 months) for
patients receiving raltitrexed, while the other studies demonstrated
no survival difference compared with 5-FU/leucovorin bolus
schedules. Although these small differences were statistically
significant, they may not be clinically relevant when clinicians
have to decide for an individual patient.
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